Immuno Chem Technologies Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 16-12-2024
- Paid Up Capital ₹ 0.10 M
as on 16-12-2024
- Company Age 9 Year, 3 Months
- Last Filing with ROC 31 Mar 2019
- Open Charges ₹ 1.79 M
as on 16-12-2024
- Revenue 3.07%
(FY 2018)
- Profit -851.51%
(FY 2018)
- Ebitda -39.07%
(FY 2018)
- Net Worth -466.26%
(FY 2018)
- Total Assets 69.35%
(FY 2018)
About Immuno Chem Technologies
The Company is engaged in the Machinery And Equipment Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.79 M.
Prashant Borse, Amruta Borse, and Ajinkya Pawar serve as directors at the Company.
- CIN/LLPIN
U74999PN2015PTC156810
- Company No.
156810
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Oct 2015
- Date of AGM
30 Sep 2019
- Date of Balance Sheet
31 Mar 2019
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Immuno Chem Technologies Private Limited offer?
Immuno Chem Technologies Private Limited offers a wide range of products and services, including Biochemistry Analyzer, Chemistry Analyzers, Pathology Lab Equipments, Microplate Reader, IVDs & Analyzers, Immunoassay Analyzer.
Who are the key members and board of directors at Immuno Chem Technologies?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ajinkya Pawar  | Director | 12-Oct-2015 | Current |
| Prashant Borse | Director | 12-Oct-2015 | Current |
| Amruta Borse | Director | 12-Oct-2015 | Current |
Financial Performance of Immuno Chem Technologies.
Immuno Chem Technologies Private Limited, for the financial year ended 2018, experienced modest growth in revenue, with a 3.07% increase. The company also saw a substantial fall in profitability, with a 851.51% decrease in profit. The company's net worth observed a substantial decline by a decrease of 466.26%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Immuno Chem Technologies?
In 2018, Immuno Chem Technologies had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 30 Dec 2017 | ₹1.79 M | Open |
How Many Employees Work at Immuno Chem Technologies?
Unlock and access historical data on people associated with Immuno Chem Technologies, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Immuno Chem Technologies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Immuno Chem Technologies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
